1例伏立康唑联合米卡芬净治疗慢性阻塞性肺疾病合并侵袭性肺曲霉菌感染患者的药学监护

doi:10.19803/j.1672-8629.20210808

中国药物警戒 ›› 2022, Vol. 19 ›› Issue (12): 1380-1383.
DOI: 10.19803/j.1672-8629.20210808

1例伏立康唑联合米卡芬净治疗慢性阻塞性肺疾病合并侵袭性肺曲霉菌感染患者的药学监护

张黎¹, 陈海涛^1,△, 陈学梁¹, 高秀蓉^2,*

¹成都市青白江区人民医院,四川成都 610300;
²成都医学院,四川成都 610500

收稿日期:2021-08-26 出版日期:2022-12-15 发布日期:2022-12-21
通讯作者: ^*高秀蓉,女,博士,副教授,临床药学。E-mail: gaomuxouzi@126.com
作者简介:张黎,女,本科,主管药师,医院药学。^Δ为并列第一作者。
基金资助:
四川省基础卫生事业发展中心2020年青年项目（SWFZ20-Q-050）

Pharmaceutical care for a case of voriconazole combined with micafungin in the treatment of chronic obstructive pulmonary disease patients with pulmonary aspergillus infection

ZHANG Li¹, CHEN Haitao^1,△, CHEN Xueliang¹, GAO Xiurong^2,*

¹Chengdu Qingbaijiang District People’s Hospital, Chengdu Sichuan 610300, China;
²Chengdu Medical College, Chengdu Sichuan 610500, China

Received:2021-08-26 Online:2022-12-15 Published:2022-12-21

摘要/Abstract

摘要： 目的分析伏立康唑联合米卡芬净治疗慢性阻塞性肺疾病（COPD）合并侵袭性曲霉菌感染的治疗方案及药学监护要点。方法临床药师通过参与1例患者的治疗与监护过程,根据不同药物在体内的代谢动力学特征,结合患者的具体情况进行药物选择,并且在治疗过程中提供药学服务。结果临床药师参与治疗后,建议使用伏立康唑联合米卡芬净联合治疗,使病情得到了缓解,避免了药品严重不良反应。结论抗真菌药物的合理选用是保障治疗COPD合并侵袭性曲霉菌感染效果的重要因素,临床药师应积极参与疑难危重症患者的药学监护。

关键词: 伏立康唑, 米卡芬净, 侵袭性肺曲霉病, 慢性阻塞性肺疾病, 药学监护

Abstract: Objective To analyze the process of treatment and priorities of pharmaceutical care during the treatment of chronic obstructive pulmonary disease (COPD) complicated with invasive aspergillosis with voriconazole combined with micafungin. Methods Clinical pharmacists participated in the treatment and monitoring of a patient, selected drugs according to the metabolic kinetic characteristics of different drugs in the body, and provided pharmaceutical care during the treatment based on the condition of the patient. Results Upon participation in the treatment, the pharmacists recommended voriconazole combined with micafungin to alleviate the condition and prevent serious adverse drug reactions. Conclusion Selection of the right antibiotics is crucial to the efficacy of treatment of COPD with invasive aspergillosis. Clinical pharmacists should actively participate in pharmaceutical care of patients in critical condition.

Key words: voriconazole, micafungin, invasive pulmonary aspergillosis, chronic obstructive pulmonary disease, pharmaceutical care

中图分类号:

R994.1

张黎, 陈海涛, 陈学梁, 高秀蓉. 1例伏立康唑联合米卡芬净治疗慢性阻塞性肺疾病合并侵袭性肺曲霉菌感染患者的药学监护[J]. 中国药物警戒, 2022, 19(12): 1380-1383.

ZHANG Li, CHEN Haitao, CHEN Xueliang, GAO Xiurong. Pharmaceutical care for a case of voriconazole combined with micafungin in the treatment of chronic obstructive pulmonary disease patients with pulmonary aspergillus infection[J]. Chinese Journal of Pharmacovigilance, 2022, 19(12): 1380-1383.

参考文献

[1] CHEN LX, CHEN DC.Update and analysis of clinical diagnosis and treatment guidelines for aspergillus infection (IDSA 2016 Edition)[J].Chinese Journal of Medicine(中国医刊), 2018,53(6): 595-598.
[2] Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease[R/OL].[2021-02-20].https://goldcopd.org.
[3] BADDLEY JW.Clinical risk factors for invasive aspergillosis[J]. Medical Mycology, 2011, 49(Suppl 1): S7-S12.
[4] BAO ZJ, XU JP, CHEN AF.Risk factors for secondary pulmonary fungal infection in patients with chronic obstructive pulmonary disease[J].Chinese Journal of Nosocomiology(中华医院感染学杂志), 2014, 24(17):4245-4247.
[5] WANG C, CHI CH, CHEN RC, et al.Guideline for primary care of chronic obstructive pulmonary disease (2018)[J]. Chinese Journal of General Practitioners(中华全科医师杂志), 2018, 17(11): 856-870.
[6] Working Group on Revision of Guiding Principles for Clinical Application of Antibiotics. Guiding Principles of Clinical Use of Antibiotics(2015)(抗菌药物临床应用指导原则2015年版)[M]. Beijing People’s Medical Publishing House, 2015.
[7] Infection Group of Chinese Thoracic Society.Chinese Journal of Tuberculosis and Respiratory Editorial Committee.Expert consensus on diagnosis and treatment of pulmonary mycosis[J].Chinese Journal of Tuberculosis and Respiratory Diseases(中华结核和呼吸杂志), 2007, 30(11):821-834.
[8] PATTERSON TF, THOMPSON GR 3RD, DENNING DW, et a1. Practice guidelines for the diagnosis and management of aspergillosis:2016 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2016, 63(4): el-e60.
[9] ZONIOS D, YAMAZAKI H,MURAYAMA N, et al.Voriconazole metabolism,toxicity,and the effect of cytochrome P450 2C19 genotype[J]. J Infect Dis, 2014, 209: 1941-1948.
[10] ZHANG XJ, CAI R, LAI B, et al.Study on the risk factors of voriconazole hepatotoxicity[J]. Hebei Medical Journal(河北医药), 2016, 38(4): 617-620.
[11] CHEN K, ZHANG X, KE X, et al.Individalized medication of voriconazole:a practice guideline of the division of therapeutic drug monitoring, Chinese pharmacological society[J]. Ther Drug Monit, 2018, 40(6): 663-674.
[12] Chinese Medical Association, Chinese Medical Association Publishing House, Chinese Society of Gastroenterology, et al. Guideline for primary care of drug-induced liver injury(2019)[J]. Chinese Journal of General Practitioners(中华全科医师杂志), 2020, 19(10):868-875.
[13] ZHOU R, CHEN ZZ.Pharmacists’participation in the treatment of a patient with complicated abdominal infection secondary to invasive fungal infection[J].Chinese Journal of Pharmacovigilance(中国药物警戒), 2020,17(2): 106-110.
[14] CHEN DC, FENG SZ, HU JD, et al.Multidisciplinary clinical evaluation of micafungin[J].The Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2014, 30(11): 1071-1078.
[15] CORNELY OA, SIDHU M, ODEYEMI I, et al.Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany[J]. Curr Med Res Opin, 2008, 24: 1743-1753.
[16] NEOH CF, LIEW D, SLAVIN MA, et al.Economic evaluation of micafungin versus caspofungin for the treatment of candidaemia and invasive candidiasis[J]. Intern Med J, 2013, 43: 668-677.
[17] SHU YQ, LI Y.Clinical effectiveness and utilization review of caspofungin and micafungin in treatment of in-vasive fungal infections in critical patients[J]. Practical Journal of Clinical Medicine(实用医院临床杂志), 2012, 9(5): 80-82.
[18] WANG FL, JIANG T, ZHENG LL.Pulmonary coinfection by aspergillus and pneumocystis jirovecii:a case report and Literature review[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2021, 41(13): 1372-1376.
[19] WANG L, GAO LJ, AN Y, et al.Diagnostic value of serum aspergillus-specific IgG and IgE in allergic bronchopulmonary aspergillosis[J].Guangxi Medical Journal(广西医学), 2020, 42(23): 3039-3042.
[20] ZHANG Y, MIU Q, JIN WT, et al.Etiological dignostic value of metagenomic next-generation sequencing in chronic pulmonary aspergillosis[J]. Chinese Journal of Clinical Medicine(中国临床医学), 2020, 27(4): 563-566.

1例伏立康唑联合米卡芬净治疗慢性阻塞性肺疾病合并侵袭性肺曲霉菌感染患者的药学监护

Pharmaceutical care for a case of voriconazole combined with micafungin in the treatment of chronic obstructive pulmonary disease patients with pulmonary aspergillus infection

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	张夏兰, 袁静, 吴斌, 秦媛媛. 甲磺酸阿帕替尼在恶性肿瘤患者的用药特征分析[J]. 中国药物警戒, 2023, 20(8): 927-932.
[2]	王然, 李轶凡, 刘小艳, 冯欣. 1例妊娠期药物暴露风险的药学监护[J]. 中国药物警戒, 2023, 20(8): 933-934.
[3]	刘婧, 夏亮, 张世杰. 1例多元药物过敏急性胰腺炎患者行药物激发试验的药学监护[J]. 中国药物警戒, 2023, 20(7): 822-824.
[4]	王国华, 黎晓蕾, 刘希萍, 董毅智, 臧琛, 徐鸿, 田纪祥, 赵静. 痰热清注射液雾化吸入治疗慢性阻塞性肺疾病Meta分析[J]. 中国药物警戒, 2023, 20(5): 544-552.
[5]	吕鹏, 张京莉, 王运红, 马芬芬, 张玉, 黄怡菲. 伏立康唑致肺移植受者皮肤鳞状细胞癌危险因素及机制研究进展[J]. 中国药物警戒, 2023, 20(5): 595-600.
[6]	胡碧原, 汪静, 郑微旗, 胡宏平, 陈泳伍. 注射用伏立康唑致自杀倾向与感觉异常1例分析[J]. 中国药物警戒, 2023, 20(4): 469-472.
[7]	杨岩, 周德喜, 吴欣俐, 薛淑雅, 丁海华, 张泉, 张云玲. 84例新型抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2023, 20(3): 334-338.
[8]	姚鑫, 葛秋格, 李亚敏, 王一帆, 李媛媛, 刘志强. 2018~2022年某院新型抗肿瘤药物消化系统不良反应分析[J]. 中国药物警戒, 2023, 20(11): 1273-1278.
[9]	郑金凤, 王景红. 1例多药联用致室性心律失常的药学监护[J]. 中国药物警戒, 2023, 20(11): 1279-1281.
[10]	苏甦, 伍诗琪, 张青霞, 闫素英. 1例吲达帕胺致粒细胞缺乏症患者的药学监护[J]. 中国药物警戒, 2023, 20(11): 1282-1285.
[11]	王燕婷, 张媛媛, 陈怡然, 孙捷, 朱宇, 杨荔艳, 吴知桂, 申丽君, 程敏, 李国辉. 1例恶性肿瘤患者抗感染与抗肿瘤治疗的平衡抉择及药学监护[J]. 中国药物警戒, 2023, 20(10): 1168-1172.
[12]	王祺茹, 左丽, 杜琼, 叶玲, 阮聪, 翟青, 徐蕊. 1例奥拉帕利致Ⅳ度骨髓抑制患者的药学监护[J]. 中国药物警戒, 2023, 20(10): 1176-1180.
[13]	孙雪林, 张攀, 胡欣. 1例维得利珠单抗治疗重症溃疡性结肠炎的药学监护[J]. 中国药物警戒, 2022, 19(7): 782-785.
[14]	唐静雅. 临床药师参与1例肠外营养相关性肝损伤治疗的药学监护[J]. 中国药物警戒, 2022, 19(7): 786-788.
[15]	李雁铭, 赵志刚. 基于循证的伊布替尼不良反应及药学监护[J]. 中国药物警戒, 2022, 19(7): 807-811.